Eyestem https://validator.w3.org/feed/docs/rss2.html 0 Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE Our Team Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes How a 14-member biotech spent just $10M on a product global pharma wants to lap up How a 14-member biotech spent just $10M on a product global pharma wants to lap up Soundararajan L, Surendran H, Patlolla N, Battu R, Stoddard J, Arrizabalaga S, Liu Z, Lingam G, Su X, Ryals RC, Pal R. Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients Eyestem announces interim safety and efficacy data from ongoing Phase I trial using Eyecyte-RPE for the treatment of Geographic Atrophy patients, in an International Conference “The Future is Here II, Exploring New Frontiers of Ocular Research”, organized by LV Prasad Eye Institute, Hyderabad b/w Jan 9-12. Surendran H, Battu R, Gopurappilly R, Vishnuprasad CN, Pal R. Our Technology Careers Contact Why India’s promising biotech industry needs more attention Eyestem receives positive recommendation from the Drug Safety Monitoring Board(DSMB) for the first set of patient injections for its pioneering Dry AMD treatment Scientific Advisors Collaboration agreement for safety and efficacy studies using iPSC-derived Dopaminergic neuronal progenitors in rodent models of Parkinson’s Disease Collaboration on modelling of inherited retinal disorders with complex mutations and developing a high-throughput drug screening platform BIRAC Innovator Award 2023 for best innovation in the area of Healthcare – Therapeutics and Vaccines Dr. Jogin Desai, Founder and CEO was named Entrepreneur of the Year for Asia 2024 at the Biospectrum Asia awards ceremony, Singapore Research Alliance Home Interventional Strategies for Parkinson Disease Subramani J, Patlolla N, Battu R, Saiyed T, Pal R Co-founders AAV – mediated gene therapy Eyestem receives positive recommendation from the Drug Safety Monitoring Board(DSMB) for the first set of patient injections for its pioneering Dry AMD treatment Eyestem to Start Human Trials for its Pioneering Dry AMD Treatment Eyestem completes first set of patient injections for its pioneering Dry AMD treatment Eyestem completes first set of patient injections for its pioneering Dry AMD treatment Eyestem to Start Human Trials for its Pioneering Dry AMD Treatment Eyestem files for IND approval for its product to treat Geographic Atrophy, the largest cause of incurable blindness in the world for people over 50 Investors National Institute of Mental Health and Neurosciences (NIMHANS) Access to clinical grade iPSC lines to facilitate global acceptability of product Development agreement with Cytespace Winner of the Biotechnology Licensing arrangement to access iPSC stem cell patents GMP Manufacturer of choice for several top ten pharma companies in the world Partnership with for manufacturing and first in human trials Animal efficacy/safety studies done at Casey Eye Institute, Oregon Health and Science University Collaboration inked to look at geographic expansion of EyeCyte-RPE™ Significant is the Economic times startup of the year award for 2022 Eyestem files for IND approval for its product to treat Geographic Atrophy, the largest cause of incurable blindness in the world for people over 50 Our Product Pipeline Retinitis pigmentosa and Eyecyte-PRP<sup>TM</sup> Eyestem announces US operations with appointment of Ravi Achar and engagement of Stradling advisors Eyestem Research moves one step closer in finding a treatment for Dry AMD and announces successful animal experiments for its flagship product.